JAZZ•benzinga•
FDA Accepts Jazz Pharma's sNDA For Zepzelca In Combination With Atezolizumab As First-Line Maintenance Treatment For People With ES-SCLC For Priority Review, With PDUFA Action Date Of October 7, 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 10, 2025 by benzinga